Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  Resverlogix Corp.    RVX   CA76128M1086

RESVERLOGIX CORP.

(RVX)
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensus 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
04/11/2019 04/12/2019 04/15/2019 04/16/2019 04/17/2019 Date
3.25(c) 3.3(c) 3.22(c) 3.315(c) 3.2(c) Last
7 622 14 850 40 585 31 328 36 885 Volume
-1.52% +1.54% -2.42% +2.95% -3.47% Change
More quotes
Company
Resverlogix Corp is Canada-based clinical-stage biotechnology company. The Company is developing apabetalone (RVX-208), a molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes.... 
More about the company
Latest news on RESVERLOGIX CORP.
08:01aRESVERLOGIX : rsquo; BETonMACE Phase 3 Trial Successfully Reaches its Targeted 2..
AQ
04/02RESVERLOGIX : Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial P..
AQ
04/01Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial ..
GL
04/01RESVERLOGIX : Announces $15.1 Million of Private Placements
AQ
03/28RESVERLOGIX : Announces Ninth Positive Data Safety Monitoring Board Recommendati..
AQ
03/27RESVERLOGIX : Announces Ninth Positive Data Safety Monitoring Board Recommendati..
AQ
03/19RESVERLOGIX : Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalone..
AQ
03/19RESVERLOGIX : Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalone..
AQ
03/18Resverlogix Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalon..
GL
03/11RESVERLOGIX : Announces Participation at Prominent Industry and Investor Confere..
AQ
More news
Analyst Recommendations on RESVERLOGIX CORP.
More recommendations
Sector news : Bio Therapeutic Drugs
04/16GILEAD SCIENCES : Insitro to Collaborate on Nonalcoholic Steatohepatitis
DJ
04/15PATRICK THOMAS : Novartis Files Application for Macular Degeneration Treatment
DJ
04/12GILEAD SCIENCES : Novo Nordisk Plan NASH Collaboration
DJ
04/08GSK wins U.S. nod for two-drug HIV combination
RE
04/08Sanofi, Alnylam Complete Research Phase of Rare Disease Alliance
DJ
More sector news : Bio Therapeutic Drugs
Chart RESVERLOGIX CORP.
Duration : Period :
Resverlogix Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESVERLOGIX CORP.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 5,64 $
Spread / Average Target 135%
Managers
NameTitle
Donald J. McCaffrey Chairman, President, CEO & Secretary
Anthony Brad Cann Chief Financial Officer
Norman C. W. Wong Chief Scientific Officer
Kelly McNeill Independent Director
Kenneth J. Zuerblis Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
RESVERLOGIX CORP.0.76%480
GILEAD SCIENCES1.12%80 637
VERTEX PHARMACEUTICALS8.47%42 687
REGENERON PHARMACEUTICALS-1.56%36 823
GENMAB5.11%10 473
SAREPTA THERAPEUTICS INC8.80%8 748